Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.


Results 1-6 of 6 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2019Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaMoujalled, D.M.; Pomilio, G.; Ghiurau, C.; Ivey, A.; Salmon, J.; Rijal, S.; Macraild, S.; Zhang, L.; Teh, T.C.; Tiong, I.S.; Lan, P.; Chanrion, M.; Claperon, A.; Rocchetti, F.; Zichi, A.; Kraus-Berthier, L.; Wang, Y.; Halilovic, E.; Morris, E.; Colland, F.; et al.
2016Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic targetAsim, M.; Massie, C.; Orafidiya, F.; PĂ©rtega-Gomes, N.; Warren, A.; Esmaeili, M.; Selth, L.; Zecchini, H.; Luko, K.; Qureshi, A.; Baridi, A.; Menon, S.; Madhu, B.; Escriu, C.; Lyons, S.; Vowler, S.; Zecchini, V.; Shaw, G.; Hessenkemper, W.; Russell, R.; et al.
2013Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionThomas, D.; Powell, J.; Vergez, F.; Segal, D.; Nguyen, N.; Baker, A.; Teh, T.; Barry, E.; Sarry, J.; Lee, E.; Nero, T.; Jabbour, A.; Giovanna, P.; Green, B.; Manenti, S.; Glaser, S.; Parker, M.; Lopez, A.; Ekert, P.; Lock, R.; et al.
2019Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemiaBell, C.C.; Fennell, K.A.; Chan, Y.C.; Rambow, F.; Yeung, M.M.; Vassiliadis, D.; Lara, L.; Yeh, P.; Martelotto, L.G.; Rogiers, A.; Kremer, B.E.; Barbash, O.; Mohammad, H.P.; Johanson, T.M.; Burr, M.L.; Dhar, A.; Karpinich, N.; Tian, L.; Tyler, D.S.; MacPherson, L.; et al.
2021CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memoryLelliott, E.J.; Kong, I.Y.; Zethoven, M.; Ramsbottom, K.M.; Martelotto, L.G.; Meyran, D.; Zhu, J.J.; Costacurta, M.; Kirby, L.; Sandow, J.J.; Lim, L.; Dominguez, P.M.; Todorovski, I.; Haynes, N.M.; Beavis, P.A.; Neeson, P.J.; Hawkins, E.D.; McArthur, G.A.; Parish, I.A.; Johnstone, R.W.; et al.
2004A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.Emanuel, S.; Gruninger, R.; Fuentas, P.; Connolly, P.; Seamon, J.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; D'Andrea, M.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; et al.